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Dr. Madoff’s remarks address three different points. First,
he addresses the difficult issue of extending the right portal
vein embolization (PVE) to segment 4 branches in case of
planned extended right hepatectomy. He states that we
improperly cited his publication [6]. We agree that right
PVE extended to segment 4 is not intended to hypertrophy
the whole left liver (segments 2, 3, and 4). Dr. Madoff must
have been confused by our use of ‘‘left lobe’’ of the liver, a
term he seems to confuse with ‘‘left liver.’’ Anatomic
classification of liver segments as well as their name varies
among different areas in the world. Nevertheless, in the
most widely accepted textbook of liver surgery [1] as well
as in most surgical centers, the left lobe is the part of the
liver located medial to the falciform ligament—that is,
segments 2 and 3 in the Couinaud nomenclature. Using
these terms, our sentence is correct and properly reflects
Dr. Madoff’s own statement. Dr. Madoff argues that his
publication does not demonstrate that segment 4 emboli-
zation improves the hypertrophy rate of the left lobe.
However, in the same reference [6], Dr. Madoff writes in
the discussion that ‘‘the experience reported herein high-
lights…the advantage of segment 4 embolization and the
advantages of embolization with small spherical particles
used in combination with coils.’’ Despite his own
statement, we recognize, as mentioned in his letter, that this
retrospective study more clearly reflects the potential
benefit of small particles over nonspherical ones, rather
than the benefit of segment 4 branches embolization. In
another sentence, he recognizes that segment 4 branch
embolization needs ‘‘extreme care to avoid reflux in seg-
ments 2 and 3 branches,…and may require substantially
more time and contrast than right PVE.’’ In another article,
surprisingly, segment 4 increased in volume after right ? 4
PVE (?26 % similarly to right PVE ?20 %); this finding
might reflect the difficulty in recognizing all segment 4
branches and/or completely occluding all of them [5].
Other centers reviewing the largest series published to date
have not found a difference in hypertrophy of the future
remnant liver between these two techniques [3]. The final
answer to this point should be provided by randomized
trial, but in the meantime, we recommend that segment 4
branch embolization should be performed only by experi-
enced interventional radiologists and when anatomy is
appropriate (large segment 4 branches) using easily con-
trollable embolic material.
Second, Dr. Madoff comments on the choice of the
embolic agent for PVE. Nearly all commercially available
embolic agents have been used for PVE and produced,
more or less, left liver hypertrophy after right PVE. From
the patient’s perspective, the choice of the ‘‘best’’ embolic
agent should be according to whether it performs better at
inducing higher hypertrophy of the future remnant liver,
whether it has a lower rate of complications but works
similarly, or both. The authors state that there is only one
‘‘small animal study’’ comparing NBCA (n-butyl-cyano-
acrylate) to spherical particles, thus supporting the use of
NBCA versus spherical particles in terms of performance
[2]. Recently, another experimental publication demon-
strated the same results [8] when comparing NBCA to
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small particles in an animal model using more recent
evaluation technologies. It is interesting, as we point out in
our review, that regeneration of the future remnant liver
seems correlated to the periportal inflammation created in
the embolized liver by the embolic material [2]. This has
been demonstrated both in animals and in humans, and this
strongly favors the use of NBCA as compared to particles,
coils, and plugs, because NBCA induces little or no peri-
portal inflammation. Concerning the complication rate, the
only large series that specifically addressed this point was
performed on patients embolized with NBCA [4]. To our
knowledge, no series including the same number of
patients and using particles specifically addressed this
point. Nevertheless, severe complications like left portal
vein thrombosis that can preclude further liver resection are
observed despite an ipsilateral approach and the use of
particles [7]. Dr. Madoff’s citations of abstracts adds little
to this debate because these series have not been published,
making their detailed analysis impossible.
Finally, Dr. Madoff comments on the benefit of an
ipsilateral versus contralateral approach to the portal tree.
Each approach carries both risks and advantages. It is also
related to the choice of the embolic material and to the
anatomic territory that needs to be treated. In a recent
review, van Gulik et al. [9] quoted a survey conducted in
the Netherlands during 2006–2007. During this period,
only 98 portal occlusions were performed in this country,
only half of them by means of percutaneous emboliza-
tion—the result of a lack of experienced interventional
radiologists. This honest statement clearly establishes that
PVE is a technique performed probably less than once a
month even in large centers, and each interventional radi-
ologist must thus feel confident with the method that he or
she uses. In our review, we wanted to honestly present the
benefits and drawbacks of each access route. Practitioners
can then make an informed choice.
Dr. Madoff’s contributions to the field of PVE are
impressive, as is his work with Nicolas Vauthey, a liver
surgeon at the MD Anderson Cancer Center, Houston,
Texas. They have made a lot to promote this technique that
was invented in Japan and modified in Europe. We thus
expect that most of the questions his remarks raise will find
more robust response than only expert opinion.
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